



OvaGene Receives Federal Grant Awards to Accelerate Innovative Gynecologic Cancer Research

FOR IMMEDIATE RELEASE

Irvine, Calif/PRNewswire/December 16, 2010-- OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized gene-based diagnostics for gynecologic cancer, is pleased to announce that it has been awarded federal grants totaling over \$516,000 under the Qualifying Therapeutic Discovery Projects (QTDP) program.

The QTDP program was established in 2010 by the Department of Health and Human Services (DHS) in conjunction with the Internal Revenue Service (IRS). Under the award guidelines, projects were judged based on their reasonable potential to produce new therapies, reduce long-term health care costs or cure cancer within 30 years. OvaGene Oncology was awarded grants for three promising research programs to accelerate the discovery and commercialization of novel molecular diagnostics for current and potentially future drugs.

"We are very pleased that the DHS recognizes the importance of OvaGene's research. The awards were highly sought after and very competitive", commented William Ricketts, Ph.D., Chief Scientific Officer for OvaGene. "The grant funds will help us accelerate our research efforts which are critical when trying to bring life changing cancer diagnostics to the patients in a timely manner. The mission of OvaGene is in perfect agreement with the goals of the QTDP program. We believe the tests we are developing will significantly improve the care of gynecologic cancer patients and reduce the unnecessary costs associated with inaccurate diagnosis or ineffective therapies."

About OvaGene Oncology

OvaGene Oncology is a molecular diagnostics company, located in Orange County California, dedicated to improving cancer care and outcomes for gynecologic cancer patients through the development of novel gene-based assays. The company plans to offer proprietary and non-proprietary molecular diagnostic assays to assist physicians in the prognosis of gynecologic cancers as well as therapy selection, including radiation and chemotherapy. There are over 11,000 cases of cervical cancer, 25,000 cases of ovarian cancer and 42,000 cases of endometrial cancer diagnosed each year in the United States. The total market for OvaGene's genomic assays is over 80,000 gynecologic cancer cases diagnosed annually. Please visit our website at www.ovagene.com for more information about our company.

Contact:

OvaGene Oncology

Jay Coonan, M.D.

Executive Vice President, Strategy and Business Development

e-mail: jcoonan@ovagene.com

Phone: 480-544 9257
